HS2
General Information
DRACP ID DRACP01043
Peptide Name HS2
Sequence CGAISLAPKLQIKES
Sequence Length 15
UniProt ID Not available
PubChem CID Not available
Origin Synthetic
Type Synthetic peptide
Classification
Active ACP Cancer targeted peptides
Activity Information
Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|---|
CT26 | Mouse colon adenocarcinoma | Carcinoma | IC50=93.5±10.7 µM | MTT assay | 24, 48, 72h | 1 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target programmed cell death protein 1
Affinity Not available
Mechanism Not available
Nature Anticancer; Antitumor
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral L
Physicochemical Information
Formula C68H120N18O21S
Absent amino acids DFHMNRTVWY
Common amino acids AIKLS
Mass 180778
Pl 8.54
Basic residues 2
Acidic residues 1
Hydrophobic residues 6
Net charge 1
Boman Index -473
Hydrophobicity 28.67
Aliphatic Index 117.33
Half Life
Mammalian: 1.2 hour
Yeast: >20 hour
E.coli: >10 hour
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 4
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 33360579
Title Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy
Year 2021
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available